Pay in 4 interest-free payments of $7.24 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
In 2015, a Cognitive Vitality Report released by the Alzheimers Drug Discovery Foundation stated that two multi-year treatment trials had found that epithalamin, from which epitalon is isolated, had imparted no severe adverse events in older adults, and that preclinical trials supported a favorable safety profile.35 Ten years later, a systematic review published in 2025 stated that information regarding critical issues about this peptides safety is missing.1 In terms of human trials, the best case we have in support of epitalons safety is a 2002 trial involving 162 patients in which no one in the epitalon group reported serious side effects.36 At the same time, the U.S
Long term effects have not been studied
Standard protocol (250 mcg 2x/day SC near injury) dominates community consensus
Preclinical toxicological data: Acute and subacute toxicity studies in rats did not reveal any mortality or significant organ toxicity, even at doses well above therapeutic doses (up to 100 times the effective dose)
The safest approach is using on alternate days
This decision fundamentally shapes how it can be accessed and used
US$ 21.53
US$ 22.22
US$ 25.00
